Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during four oral presentations at upcoming medical conferences. Data will be presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) in New Orleans (June 5-8), the National Lipid Association (NLA) Scientific Sessions in Chicago (June 11-14) and ENDO 2026, the Endocrine Society’s annual meeting in Chicago (June 13-16).
“People living with sHTG are at risk of acute pancreatitis, a debilitatingly painful complication that can potentially be life-threatening and cause other serious health consequences. Standard lipid-lowering therapies only offer modest benefits, underscoring the urgent need for innovative new treatment options,” said Sam Tsimikas, M.D., senior vice president, global cardiovascular development, Ionis. “The data that will be presented expand the understanding of how olezarsen impacts patients across different clinical and treatment backgrounds, and we look forward to sharing these results with the medical community.”
